vs
Side-by-side financial comparison of PJT Partners Inc. (PJT) and Bio-Techne (TECH). Click either name above to swap in a different company.
PJT Partners Inc. is the larger business by last-quarter revenue ($531.4M vs $295.9M, roughly 1.8× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs 10.0%, a 2.8% gap on every dollar of revenue. On growth, PJT Partners Inc. posted the faster year-over-year revenue change (12.9% vs -6.4%). Over the past eight quarters, PJT Partners Inc.'s revenue compounded faster (27.5% CAGR vs 4.2%).
PJT Partners, Inc. is a global advisory-focused investment bank, founded in October 2015 as part of The Blackstone Group's spin-off of its financial and strategic advisory services businesses.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
PJT vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $531.4M | $295.9M |
| Net Profit | $53.4M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | 23.1% | 18.4% |
| Net Margin | 10.0% | 12.8% |
| Revenue YoY | 12.9% | -6.4% |
| Net Profit YoY | 4.0% | 68.3% |
| EPS (diluted) | — | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $531.4M | $295.9M | ||
| Q3 25 | $442.3M | — | ||
| Q2 25 | $401.1M | $317.0M | ||
| Q1 25 | $321.9M | $316.2M | ||
| Q4 24 | $470.5M | $297.0M | ||
| Q3 24 | $320.3M | $289.5M | ||
| Q2 24 | $358.1M | $306.1M | ||
| Q1 24 | $327.1M | $303.4M |
| Q4 25 | $53.4M | $38.0M | ||
| Q3 25 | $39.8M | — | ||
| Q2 25 | $32.9M | $-17.7M | ||
| Q1 25 | $54.0M | $22.6M | ||
| Q4 24 | $51.3M | $34.9M | ||
| Q3 24 | $22.1M | $33.6M | ||
| Q2 24 | $28.3M | $40.6M | ||
| Q1 24 | $32.6M | $49.1M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
| Q4 25 | 23.1% | 18.4% | ||
| Q3 25 | 20.6% | — | ||
| Q2 25 | 19.1% | -7.5% | ||
| Q1 25 | 16.3% | 12.2% | ||
| Q4 24 | 21.9% | 16.0% | ||
| Q3 24 | 15.4% | 13.8% | ||
| Q2 24 | 18.0% | 15.0% | ||
| Q1 24 | 16.5% | 22.1% |
| Q4 25 | 10.0% | 12.8% | ||
| Q3 25 | 9.0% | — | ||
| Q2 25 | 8.2% | -5.6% | ||
| Q1 25 | 16.8% | 7.1% | ||
| Q4 24 | 10.9% | 11.7% | ||
| Q3 24 | 6.9% | 11.6% | ||
| Q2 24 | 7.9% | 13.3% | ||
| Q1 24 | 10.0% | 16.2% |
| Q4 25 | — | $0.24 | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $0.14 | ||
| Q4 24 | — | $0.22 | ||
| Q3 24 | — | $0.21 | ||
| Q2 24 | — | $0.26 | ||
| Q1 24 | — | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $538.9M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $308.2M | $2.0B |
| Total Assets | $1.8B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $538.9M | $172.9M | ||
| Q3 25 | $400.5M | — | ||
| Q2 25 | $214.6M | $162.2M | ||
| Q1 25 | $194.3M | $140.7M | ||
| Q4 24 | $483.9M | $177.5M | ||
| Q3 24 | $148.8M | $187.5M | ||
| Q2 24 | $164.2M | $152.9M | ||
| Q1 24 | $215.5M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $308.2M | $2.0B | ||
| Q3 25 | $228.6M | — | ||
| Q2 25 | $167.4M | $1.9B | ||
| Q1 25 | $148.8M | $2.0B | ||
| Q4 24 | $187.0M | $2.1B | ||
| Q3 24 | $159.1M | $2.1B | ||
| Q2 24 | $133.8M | $2.1B | ||
| Q1 24 | $174.6M | $2.0B |
| Q4 25 | $1.8B | $2.5B | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $1.5B | $2.6B | ||
| Q1 25 | $1.4B | $2.6B | ||
| Q4 24 | $1.6B | $2.7B | ||
| Q3 24 | $1.6B | $2.7B | ||
| Q2 24 | $1.4B | $2.7B | ||
| Q1 24 | $1.3B | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $155.7M | — |
| Free Cash FlowOCF − Capex | $138.6M | — |
| FCF MarginFCF / Revenue | 26.1% | — |
| Capex IntensityCapex / Revenue | 3.2% | — |
| Cash ConversionOCF / Net Profit | 2.92× | — |
| TTM Free Cash FlowTrailing 4 quarters | $480.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $155.7M | — | ||
| Q3 25 | $256.1M | — | ||
| Q2 25 | $190.4M | $98.2M | ||
| Q1 25 | $-75.9M | $41.1M | ||
| Q4 24 | $195.7M | $84.3M | ||
| Q3 24 | $180.5M | $63.9M | ||
| Q2 24 | $193.6M | $75.5M | ||
| Q1 24 | $-38.8M | $81.0M |
| Q4 25 | $138.6M | — | ||
| Q3 25 | $240.9M | — | ||
| Q2 25 | $178.9M | $93.3M | ||
| Q1 25 | $-77.9M | $31.0M | ||
| Q4 24 | $195.3M | $77.5M | ||
| Q3 24 | $178.5M | $54.7M | ||
| Q2 24 | $193.0M | $57.5M | ||
| Q1 24 | $-39.2M | $64.5M |
| Q4 25 | 26.1% | — | ||
| Q3 25 | 54.5% | — | ||
| Q2 25 | 44.6% | 29.4% | ||
| Q1 25 | -24.2% | 9.8% | ||
| Q4 24 | 41.5% | 26.1% | ||
| Q3 24 | 55.7% | 18.9% | ||
| Q2 24 | 53.9% | 18.8% | ||
| Q1 24 | -12.0% | 21.3% |
| Q4 25 | 3.2% | — | ||
| Q3 25 | 3.4% | — | ||
| Q2 25 | 2.9% | 1.5% | ||
| Q1 25 | 0.6% | 3.2% | ||
| Q4 24 | 0.1% | 2.3% | ||
| Q3 24 | 0.6% | 3.2% | ||
| Q2 24 | 0.1% | 5.9% | ||
| Q1 24 | 0.1% | 5.4% |
| Q4 25 | 2.92× | — | ||
| Q3 25 | 6.43× | — | ||
| Q2 25 | 5.79× | — | ||
| Q1 25 | -1.41× | 1.82× | ||
| Q4 24 | 3.81× | 2.42× | ||
| Q3 24 | 8.15× | 1.90× | ||
| Q2 24 | 6.84× | 1.86× | ||
| Q1 24 | -1.19× | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PJT
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
